A Phase I Open Label Safety Study to Evaluate the Pharmacokinetic Profile and Tolerance of Mibefradil Dose Finding in Subjects with Recurrent High-Grade Glioma Undergoing Standard. Repeated Temozolomide Treatment (TAU-2010-1)


Total Award Amount

  • 8000.00
  • Direct Costs

  • 5442.00
  • Sponsor Award Id

  • ABTC 1101
  • Contributor

  • Hassan Fathallah-Shaykh M.D., Ph.D.   Investigator  
  • Louis Nabors M.D.   Principal Investigator  
  • Xiaosi Han   Investigator